↓ Skip to main content

FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer

Overview of attention for article published in Journal for Immunotherapy of Cancer, February 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)

Mentioned by

news
1 news outlet
twitter
30 tweeters
googleplus
1 Google+ user

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
56 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
Published in
Journal for Immunotherapy of Cancer, February 2017
DOI 10.1186/s40425-017-0217-6
Pubmed ID
Authors

Stefan N. Symeonides, Stephen M. Anderton, Alan Serrels

Abstract

Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibrotic and immuno-suppressive pancreatic tumour niche, and showed that FAK inhibitors can be used in combination with immune checkpoint blockade and gemcitabine chemotherapy to significantly delay pancreatic tumour progression. This study further supports the use of FAK inhibitors in combination with immunotherapy.

Twitter Demographics

The data shown below were collected from the profiles of 30 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
United States 1 2%
France 1 2%
Unknown 53 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 17 30%
Researcher 14 25%
Student > Master 11 20%
Student > Bachelor 3 5%
Other 2 4%
Other 3 5%
Unknown 6 11%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 17 30%
Medicine and Dentistry 13 23%
Pharmacology, Toxicology and Pharmaceutical Science 6 11%
Agricultural and Biological Sciences 4 7%
Immunology and Microbiology 4 7%
Other 5 9%
Unknown 7 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2018.
All research outputs
#962,395
of 18,745,348 outputs
Outputs from Journal for Immunotherapy of Cancer
#181
of 1,995 outputs
Outputs of similar age
#23,631
of 270,720 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 18,745,348 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,995 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.8. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,720 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them